Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 7/20 | 0.39 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22172725 | 0.92 | MAPK1 (0.43) | MAPK1MAPK3NAMPTCYP3A4CYP2C8 | |
| SCHEMBL2279054 | 0.89 | MAPK1 (0.48) | MAPK1MAPK3NAMPTCYP3A4CYP2C8 | |
| SCHEMBL1199749 | 0.84 | ALDH1A1 (0.43) | MAPK1NAMPTWNT3ACNR1MEN1 | |
| SCHEMBL2274299 | 0.82 | GPR119 (0.52) | NAMPTWNT3A | |
| SCHEMBL18113533 | 0.81 | MAPK1 (0.42) | MAPK1MAPK3CYP3A4CYP2C8CNR1 | |
| SCHEMBL12374279 | 0.81 | MAPK1 (0.47) | MAPK1MAPK3NAMPTCYP3A4CYP2C8 | |
| SCHEMBL2274285 | 0.80 | MAPK1 (0.38) | MAPK1MAPK3CNR1MEN1KMT2A | |
| SCHEMBL18113505 | 0.79 | MAPK1 (0.42) | MAPK1MAPK3CNR1MEN1KMT2A | |
| SCHEMBL12403790 | 0.78 | MAPK1 (0.48) | MAPK1MAPK3NAMPTCYP3A4CYP2C8 | |
| SCHEMBL12374252 | 0.78 | MAPK1 (0.37) | MAPK1MAPK3NAMPTCYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115058-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2021-04-22 | — | — | US | disclosed |
| US-10934304-B2 | Spirocyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2020-07-02 | — | — | US | disclosed |
| WO-2018067512-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| EP-2260031-B1 | COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2260031-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | Schering Corporation (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009105500-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115058-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | MAPK1 3219/4885MAPK3 3010/4885NAMPT 416/4885 |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | MAPK1 1/4885MAPK3 6/4885NAMPT 1183/4885 |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | MAPK1 3219/4885MAPK3 3010/4885NAMPT 416/4885 |
| US-10934304-B2 | Spirocyclic compounds | PKD1, AR, PKD2 | MAPK1 3219/4885MAPK3 3010/4885NAMPT 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.